At1g63370 Antibody

What is At1g63370 and why are antibodies against it valuable for plant research?

At1g63370 is a gene locus in Arabidopsis thaliana that encodes a protein involved in plant cellular processes. Developing antibodies against this protein enables researchers to track its expression, localization, and interactions using immunological techniques such as western blotting, immunoprecipitation, and immunohistochemistry. These antibodies serve as essential tools for understanding the protein's biological function, similar to how researchers have developed antibodies against various important proteins in mammalian systems .

The validated antibodies provide multiple research advantages: monitoring protein expression levels under various conditions, determining subcellular localization, detecting protein modifications, analyzing protein-protein interactions, and confirming genetic manipulation outcomes. When properly characterized, At1g63370 antibodies enable reproducible detection across various experimental platforms, making them indispensable tools for plant molecular biology research.

What types of antibodies can be developed against At1g63370 and how do they differ in research applications?

Several antibody types can be developed against At1g63370, each with distinct characteristics and experimental applications:

• Polyclonal antibodies: Generated by immunizing animals (typically rabbits) with At1g63370 peptides or recombinant proteins. These recognize multiple epitopes on the target protein, providing robust detection but potentially less specificity. They are particularly useful for applications requiring high sensitivity like western blotting and immunoprecipitation.

• Monoclonal antibodies: Produced from single B-cell clones, these target specific epitopes with high precision. While potentially less sensitive than polyclonals, their consistent performance across experiments makes them valuable for quantitative studies. Their specificity parallels the carefully characterized PD-1 antibody clones described by researchers for immunotherapy applications .

• Recombinant antibodies: Generated using molecular biology techniques, these offer precise control over antibody properties and production consistency, eliminating batch variation concerns.

• Nanobodies: Single-domain antibody fragments derived from camelid heavy-chain antibodies, similar to the llama nanobodies developed for HIV research . Their small size (approximately 15 kDa) allows them to access restricted epitopes that might be inaccessible to conventional antibodies, making them potentially valuable for At1g63370 conformation studies.

The choice of antibody format should align with the specific experimental requirements, considering factors like epitope accessibility, required specificity, and application conditions.

What validation methods ensure At1g63370 antibody specificity and functionality?

Rigorous validation is essential for all antibodies used in research. For At1g63370 antibodies, implement these methodological approaches:

• Genetic validation:

  • Test antibody reactivity in wild-type versus At1g63370 knockout/knockdown plants

  • Compare signal in plants overexpressing At1g63370 versus controls

  • Analyze tissue-specific expression patterns against known transcriptomic data

• Biochemical validation:

  • Perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide before use

  • Test reactivity against recombinant At1g63370 protein

  • Assess cross-reactivity against closely related plant proteins

  • Conduct immunoprecipitation followed by mass spectrometry to confirm target specificity

• Epitope mapping:

  • Determine the exact binding region using peptide arrays or deletion mutants

  • Compare recognition patterns across species with conserved At1g63370 homologs

  • Perform cross-blocking experiments similar to those done with PD-1 antibodies to identify epitope overlap between different antibody clones

• Application-specific validation:

  • For western blotting: confirm band size, absence in knockout material

  • For immunoprecipitation: verify protein identity by mass spectrometry

  • For immunohistochemistry: compare with fluorescent protein fusions

Proper validation protocols should be systematically documented and reported alongside experimental results to ensure reproducibility and data reliability.

What are the optimal conditions for At1g63370 antibody use in western blotting?

Successful western blotting with At1g63370 antibodies requires methodical optimization of multiple parameters:

Sample Preparation:

• Extract proteins from plant tissues using buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and protease inhibitor cocktail

• Include reducing agents (DTT or β-mercaptoethanol) to expose epitopes in denatured proteins

• Heat samples at 95°C for 5 minutes in sample buffer before loading

• Load 20-40 μg total protein per lane for standard detection

Electrophoresis and Transfer:

• Use 10-12% acrylamide gels for optimal resolution based on At1g63370's molecular weight

• Transfer to PVDF membranes at 100V for 60-90 minutes in cold transfer buffer containing 20% methanol

• Verify transfer efficiency using reversible protein stains like Ponceau S

Antibody Incubation:

• Block membranes with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Dilute primary antibody between 1:1000-1:5000 in blocking solution

• Incubate overnight at 4°C with gentle rocking

• Wash 3-4 times with TBST, 5-10 minutes per wash

• Incubate with HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

Signal Detection and Optimization:

• Develop using enhanced chemiluminescence reagents

• Optimize exposure time to prevent signal saturation

• Consider using fluorescent secondary antibodies for quantitative analysis

The table below shows optimization results from a representative experiment:

These conditions may require further refinement based on the specific At1g63370 antibody being used, similar to how researchers must optimize conditions for each antibody in various systems .

How should immunoprecipitation experiments with At1g63370 antibodies be designed and executed?

Immunoprecipitation (IP) experiments with At1g63370 antibodies require careful experimental design and execution:

Lysate Preparation:

• Harvest fresh plant tissue and flash-freeze in liquid nitrogen

• Grind tissue to fine powder while maintaining freezing temperatures

• Extract in IP buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, protease inhibitors)

• Clarify lysate by centrifugation at 14,000×g for 15 minutes at 4°C

• Pre-clear lysate with protein A/G beads for 1 hour at 4°C to reduce non-specific binding

Antibody Binding:

• Use 2-5 μg of At1g63370 antibody per 500 μg of total protein

• Incubate antibody with lysate for 2-4 hours or overnight at 4°C with gentle rotation

• Add 30-50 μl protein A/G magnetic beads and incubate for additional 1-2 hours

• Alternatively, pre-couple antibody to beads before adding to lysate

Washing and Elution:

• Perform 4-5 washes with IP buffer containing decreasing detergent concentrations

• Consider a final wash with detergent-free buffer

• Elute proteins by boiling in SDS-PAGE sample buffer for 5 minutes at 95°C

• For native elution, use excess immunizing peptide or low pH glycine buffer

Critical Controls:

• Input control: 5-10% of lysate used for IP

• IgG control: non-specific IgG from same species as At1g63370 antibody

• Knockout/knockdown control: tissue lacking At1g63370 expression

• Peptide competition: antibody pre-incubated with immunizing peptide

Downstream Analysis:

• Western blotting to confirm At1g63370 pull-down

• Silver staining to visualize co-precipitated proteins

• Mass spectrometry to identify interaction partners

For studying protein-protein interactions, crosslinkers like formaldehyde (1%) or DSP (2 mM) can be applied to tissues before lysis. This approach has been successfully used in various antibody-based studies of protein complexes, including those utilizing PD-1 specific antibodies in immune research .

What controls and optimization strategies are essential for immunofluorescence with At1g63370 antibodies?

Immunofluorescence microscopy with At1g63370 antibodies requires rigorous controls and optimization to ensure specific localization:

Sample Preparation Optimization:

• Test multiple fixatives: 4% paraformaldehyde, cold methanol, or combination protocols

• Optimize fixation time (10-30 minutes) to preserve antigen while maintaining tissue structure

• Evaluate permeabilization methods (0.1-0.5% Triton X-100, 0.05-0.1% Tween-20, or saponin)

• Test antigen retrieval methods if signal is weak (citrate buffer, EDTA, or enzymatic treatment)

Antibody Incubation Parameters:

• Determine optimal blocking solution (3-5% BSA, normal serum, or commercial blockers)

• Test primary antibody dilutions (1:100-1:1000) and incubation conditions

• Optimize washing steps to minimize background while preserving specific signal

• Select appropriate fluorophore-conjugated secondary antibodies based on microscopy setup

Essential Controls:

• Primary antibody omission: Apply only secondary antibody to detect non-specific binding

• Isotype control: Use non-specific antibody of same isotype and concentration

• Absorption control: Pre-incubate antibody with immunizing peptide or recombinant protein

• Genetic controls: Compare signal in knockout/knockdown versus wild-type plants

• Co-localization controls: Use markers for cellular compartments to confirm localization pattern

Advanced Validation:

• Use multiple antibodies targeting different epitopes to confirm localization

• Compare antibody staining with fluorescent protein fusions of At1g63370

• Perform super-resolution microscopy for precise subcellular localization

• Quantify signal intensity across different cellular compartments

Troubleshooting Guide:

These strategies parallel approaches used in antibody validation studies for other research systems, where careful blocking experiments and controls are essential for specificity determination .

How can At1g63370 antibodies be employed to analyze protein complexes and interaction networks?

At1g63370 antibodies provide powerful tools for unraveling protein interaction networks through multiple complementary approaches:

Co-immunoprecipitation (Co-IP) Analysis:

• Perform standard IP with At1g63370 antibodies under native conditions

• Analyze precipitated proteins by mass spectrometry for unbiased discovery

• Verify specific interactions by western blotting with antibodies against suspected partners

• Use crosslinking agents (DSP, formaldehyde) to capture transient interactions

• Conduct reciprocal Co-IPs to confirm bidirectional interaction

Proximity Labeling Approaches:

• Combine At1g63370 antibodies with proximity labeling techniques

• Use antibodies to validate BioID or APEX2 proximity labeling results

• Compare interaction maps generated through different methodologies

• Analyze interaction dynamics under different physiological conditions

Size Exclusion Chromatography with Antibody Detection:

• Fractionate plant extracts by size exclusion chromatography

• Analyze fractions by western blotting with At1g63370 antibodies

• Determine native complex size and composition

• Compare complex formation across different tissues or treatments

Chromatin Immunoprecipitation (ChIP) for DNA-Binding Partners:

• If At1g63370 functions in transcriptional complexes, use ChIP to identify DNA targets

• Combine with Re-ChIP (sequential ChIP) to identify co-binding partners on chromatin

• Correlate binding sites with transcriptional outcomes

• Map genome-wide binding patterns through ChIP-seq

Advanced Microscopy Applications:

• Implement Proximity Ligation Assay (PLA) to visualize and quantify protein interactions in situ

• Use Fluorescence Resonance Energy Transfer (FRET) with labeled antibodies to detect close associations

• Apply Stimulated Emission Depletion (STED) microscopy for super-resolution co-localization

• Quantify co-localization coefficients through image analysis software

These methods can reveal the functional network of At1g63370, similar to approaches used in studying protein complexes in other systems. The search results on llama nanobodies suggest that novel antibody formats could further enhance sensitivity in detecting protein interactions .

How should contradictory results with At1g63370 antibodies be systematically investigated?

When faced with contradictory results using At1g63370 antibodies, implement this systematic troubleshooting framework:

Antibody Validation Assessment:

• Re-validate antibody specificity using western blotting against wild-type and knockout samples

• Test multiple antibody lots and sources to identify batch-specific issues

• Perform epitope mapping to confirm recognition sites remain accessible under experimental conditions

• Consider generating new antibodies against different epitopes for orthogonal validation

Experimental Variables Analysis:

• Document all buffer compositions, incubation times, and temperatures across experiments

• Test multiple protein extraction methods to account for compartmentalization or membrane association

• Evaluate fixation conditions that might affect epitope accessibility in microscopy

• Analyze tissue-specific or developmental factors that could affect protein expression or modification

Protein Modification Investigation:

• Check for post-translational modifications that might mask epitopes under certain conditions

• Assess protein conformation changes that could alter antibody recognition

• Evaluate proteolytic processing that might generate fragments with different antibody reactivity

• Consider protein-protein interactions that could block antibody binding sites

Orthogonal Approaches:

• Implement epitope tagging (HA, FLAG, GFP) for alternative detection methods

• Use mass spectrometry for unambiguous protein identification

• Employ RNA analysis techniques to correlate protein detection with transcript levels

• Consider genetic approaches to manipulate protein abundance and confirm antibody specificity

Methodological Framework:

• Document contradictory results with photographs and detailed protocols

• Design controlled experiments testing one variable at a time

• Implement statistical analysis to determine significance of differences

• Consider independent laboratory validation for critical findings

This systematic approach parallels the rigorous methodology seen in the COVID-19 study, where researchers carefully defined AT1R autoantibody positivity criteria rather than relying solely on average values, demonstrating how methodological precision can resolve apparent contradictions .

What advanced strategies can optimize At1g63370 antibodies for chromatin immunoprecipitation studies?

Optimizing At1g63370 antibodies for Chromatin Immunoprecipitation (ChIP) applications requires specific considerations beyond standard immunoprecipitation:

Antibody Selection and Validation:

• Test multiple antibodies recognizing different At1g63370 epitopes

• Prioritize antibodies recognizing native (non-denatured) protein conformations

• Validate ChIP-grade quality through pilot experiments with known targets

• Consider developing monoclonal antibodies specifically for ChIP applications

Crosslinking Optimization:

• Test formaldehyde concentrations ranging from 0.1% to 1%

• Optimize crosslinking time (5-15 minutes) to balance efficiency and reversibility

• Consider dual crosslinking with EGS or DSG for protein-protein interactions

• Evaluate crosslinking quenching conditions (glycine concentration and time)

Chromatin Preparation:

• Optimize sonication parameters for target fragment size (200-500 bp)

• Verify fragmentation by agarose gel electrophoresis before proceeding

• Test different sonication buffers to preserve protein epitopes

• Consider enzymatic fragmentation alternatives (MNase) for certain applications

IP Protocol Refinement:

• Determine optimal antibody amount through titration (2-10 μg per sample)

• Test pre-clearing strategies to reduce background

• Optimize wash stringency to balance signal retention with specificity

• Implement controlled elution conditions for consistent chromatin recovery

Controls and Validation Framework:

• Input chromatin (pre-IP material): 5-10% of starting material

• IgG control: matched isotype from same species as At1g63370 antibody

• Positive control: antibody against ubiquitous chromatin protein (e.g., histone H3)

• Negative control regions: genomic regions not expected to bind At1g63370

• Spike-in controls: exogenous chromatin for normalization

ChIP-seq Considerations:

• Ensure sufficient sequencing depth (20-40 million reads minimum)

• Implement appropriate peak-calling algorithms

• Validate key binding sites by ChIP-qPCR

• Correlate binding with gene expression data

For bioinformatic analysis, the table below outlines recommended parameters:

This methodical approach follows similar principles to those used in antibody validation studies, where careful characterization of antibody binding properties is essential for data interpretation .

What factors contribute to high background or non-specific signals with At1g63370 antibodies?

High background is a common challenge in antibody-based experiments. For At1g63370 antibodies, consider these causes and solutions:

Antibody-Related Factors:

• Excessive concentration: Perform titration experiments to determine optimal dilution

• Cross-reactivity: Test against knockout samples and closely related proteins

• Poor quality: Evaluate antibody purity by SDS-PAGE and consider affinity purification

• Batch variation: Compare performance of different lots using standardized samples

Sample Preparation Issues:

• Incomplete blocking: Extend blocking time or test alternative blocking agents

• Insufficient washing: Increase wash volume, duration, and detergent concentration

• Protein overloading: Reduce sample amount to prevent non-specific binding

• Tissue autofluorescence: Include unstained controls and use appropriate filters

Technical Parameters:

• Detection sensitivity: Adjust exposure settings to minimize background amplification

• Incubation conditions: Compare room temperature versus 4°C incubations

• Secondary antibody cross-reactivity: Test different suppliers and pre-adsorbed secondaries

• Buffer compatibility: Ensure buffer components don't interfere with antibody binding

Experimental Design Improvements:

• Include additional blocking agents (normal serum from secondary antibody species)

• Pre-clear samples with beads before immunoprecipitation

• Pre-adsorb antibody with plant extracts from knockout material

• Implement tandem purification strategies for complex samples

Systematic Troubleshooting Approach:

• Establish baseline performance with positive and negative controls

• Change one parameter at a time and document results

• Quantify signal-to-noise ratio for objective comparison

• Create standardized protocols once optimal conditions are determined

This methodical approach to troubleshooting parallels the careful antibody characterization described in the PD-1 study, where researchers systematically tested multiple antibody clones to determine optimal conditions for specificity .

How can cross-reactivity issues with At1g63370 antibodies be identified and addressed?

Cross-reactivity in plant antibodies is a significant concern due to gene duplication and protein family conservation. For At1g63370 antibodies, implement this systematic approach:

Computational Prediction:

• Perform BLAST analysis of the immunizing peptide/protein against the plant proteome

• Identify proteins with sequence similarity that could be recognized by the antibody

• Evaluate conservation of the epitope region across related proteins

• Use epitope prediction algorithms to identify potential cross-reactive epitopes

Experimental Verification:

• Test antibody against recombinant proteins of close homologs

• Perform western blotting in wild-type versus At1g63370 knockout tissue

• Evaluate signal in tissues known to express or not express At1g63370

• Conduct peptide competition assays with immunizing and non-target peptides

Cross-Reactivity Mapping:

• Use peptide arrays to identify exact binding epitopes

• Perform epitope mutation analysis to identify critical binding residues

• Test recognition of post-translationally modified versus unmodified proteins

• Analyze multiple antibodies against different epitopes for convergent results

Mitigation Strategies:

• Immunoaffinity purification against specific epitopes

• Pre-absorption with recombinant proteins of potential cross-reactive targets

• Generation of monoclonal antibodies against unique epitopes

• Development of alternative detection reagents (nanobodies, aptamers)

Interpretation Framework:

• Document all known cross-reactivities in laboratory protocols

• Include appropriate controls in all experiments

• Consider multiple detection methods for critical findings

• Acknowledge limitations in publications and reports

This approach to characterizing and addressing cross-reactivity is similar to the systematic cross-blocking experiments performed with PD-1 antibodies, where researchers carefully mapped the binding specificities of multiple antibody clones to determine their precise epitopes and potential overlaps .

What quality control methods ensure consistent At1g63370 antibody performance across experiments?

Maintaining antibody consistency is crucial for reproducible research. Implement these quality control procedures for At1g63370 antibodies:

Standard Operating Procedures:

• Develop detailed protocols for antibody handling, storage, and use

• Create aliquoting strategies to minimize freeze-thaw cycles

• Establish standard dilutions and incubation conditions

• Document lot numbers, receipt dates, and storage locations

Reference Standards Creation:

• Prepare large batches of positive control samples (plant extracts expressing At1g63370)

• Generate recombinant protein standards at known concentrations

• Create knockout control samples as negative references

• Develop stable cell lines expressing At1g63370 as consistent sources

Routine Performance Testing:

• Perform western blot analysis with reference samples before each experimental series

• Measure binding affinity using ELISA with standard curves

• Test immunoprecipitation efficiency with consistent input material

• Document performance metrics in laboratory notebooks or databases

Advanced Characterization:

• Periodically verify antibody purity by SDS-PAGE and mass spectrometry

• Assess antibody functionality after storage using activity assays

• Check for modifications to the antibody (deamidation, oxidation, aggregation)

• Validate epitope recognition consistency through peptide arrays

Quantitative Metrics for Documentation:

Batch Transition Protocol:

• Perform side-by-side testing of old and new antibody batches

• Document comparative performance across all relevant applications

• Adjust protocols as needed based on performance differences

• Maintain overlap period where both batches are available

These quality control approaches align with the methodological rigor demonstrated in antibody analysis techniques like ESI-TOF LC/MS, which can provide molecular-level characterization of antibody consistency .

How can nanobody technology enhance At1g63370 research applications?

Nanobodies represent an emerging technology with significant potential for advancing At1g63370 research, offering several advantages over conventional antibodies:

Structural and Biochemical Advantages:

• Small size (~15 kDa) enables access to cryptic epitopes inaccessible to conventional antibodies

• High stability under extreme conditions (temperature, pH, detergents)

• Efficient expression in bacterial and plant systems

• Monomeric nature without Fc regions reduces non-specific interactions

• Rapid tissue penetration for in vivo applications

Research Applications for At1g63370:

• Super-resolution microscopy with minimal linkage error for precise localization

• Intracellular expression as "intrabodies" to track or block At1g63370 function

• Protein crystallization chaperones to determine At1g63370 structure

• Affinity reagents for highly specific protein purification

• Biosensors to detect At1g63370 conformational changes or modifications

Development Strategies:

• Immunize camelids (llamas, alpacas) with purified At1g63370 protein or peptides

• Screen nanobody libraries using phage or yeast display technologies

• Select high-affinity binders through rigorous screening processes

• Engineer multivalent nanobodies for enhanced avidity and specificity

Comparative Advantages Table:

The llama nanobody technology described in the HIV research demonstrates the potential power of this approach, where nanobodies showed remarkable neutralization capacity (96% of diverse HIV-1 strains) . Similar approaches could revolutionize At1g63370 research by providing unprecedented access to conformational epitopes and enabling novel experimental approaches.

What mass spectrometry approaches can complement antibody-based At1g63370 research?

Mass spectrometry (MS) provides powerful orthogonal approaches that complement and enhance antibody-based studies of At1g63370:

Antibody-Coupled MS Applications:

• Immunoprecipitation-mass spectrometry (IP-MS) to identify At1g63370 interaction partners

• Targeted proteomics (PRM/MRM) following antibody enrichment for sensitive quantification

• Crosslinking MS to map interaction interfaces at amino acid resolution

• Hydrogen-deuterium exchange MS to study conformational dynamics upon binding

Protein Characterization Applications:

• Absolute quantification using isotope-labeled peptide standards

• Post-translational modification mapping (phosphorylation, ubiquitination, etc.)

• Protein turnover studies using stable isotope labeling (SILAC, TMT)

• Intact protein analysis to detect variant forms and processing events

Technical Considerations for Plant Samples:

• Optimize protein extraction to reduce interference from plant-specific compounds

• Implement appropriate fractionation methods to enhance coverage of low-abundance proteins

• Select ideal proteases beyond trypsin (Lys-C, Glu-C) for optimal peptide coverage

• Develop plant-specific MS methods accounting for unique post-translational modifications

Integrated Workflows:

• Validation of Antibody Specificity:

  • Immunoprecipitate with At1g63370 antibody

  • Identify all pulled-down proteins by LC-MS/MS

  • Verify At1g63370 as the primary target

  • Document any cross-reactive proteins

• Interaction Network Analysis:

  • Perform IP-MS under different conditions

  • Filter against appropriate controls (IgG, knockout)

  • Validate key interactions by reciprocal IP

  • Map interaction changes during development or stress responses

• Quantitative Analysis:

  • Develop SRM/MRM assays for At1g63370-specific peptides

  • Create calibration curves using synthetic peptides

  • Measure absolute protein abundance across samples

  • Compare with antibody-based quantification methods

The ESI-TOF LC/MS approach described in the fourth search result demonstrates how mass spectrometry can be used for detailed antibody characterization, but similar principles apply to studying the target proteins themselves .

How can CRISPR-based technologies integrate with antibody methods for advanced At1g63370 research?

CRISPR technology offers innovative approaches that can synergize with antibody-based methods for At1g63370 research:

Genome Engineering for Antibody Validation:

• Generate precise At1g63370 knockout plants to confirm antibody specificity

• Create epitope-tagged At1g63370 at the endogenous locus for validated detection

• Introduce specific mutations to map antibody epitopes in vivo

• Develop reporter lines to correlate antibody signals with live-cell visualization

Alternative Chromatin Profiling Methods:

• Implement CUT&RUN or CUT&Tag using At1g63370 antibodies for enhanced chromatin profiling

• Develop CRISPR-based chromatin profiling as alternative to ChIP

• Compare antibody-based and CRISPR-based chromatin mapping results

• Integrate datasets to generate high-confidence binding profiles

Proximity Labeling Approaches:

• Combine CRISPR knock-in of BioID or APEX2 fusions with antibody validation

• Use endogenous tagging to verify antibody specificity and sensitivity

• Create conditional proximity labeling systems to study dynamic interactions

• Compare interactomes identified by antibody-based versus enzyme-based methods

Functional Genomics Integration:

• Generate CRISPR interference or activation systems targeting At1g63370

• Use antibodies to quantify protein expression changes

• Correlate phenotypic outcomes with protein levels and localization

• Develop functional readouts for antibody-detected interactions

Workflow Integration Strategy:

• CRISPR modification of At1g63370:

  • Design knock-in of small epitope tag (HA, FLAG)

  • Validate tag expression and function

  • Compare commercial tag antibodies with At1g63370-specific antibodies

  • Establish optimal detection conditions for each approach

• Multi-modal protein interaction analysis:

  • Perform standard antibody-based co-immunoprecipitation

  • Generate CRISPR knock-in of proximity labeling enzyme

  • Compare and integrate interaction datasets

  • Validate key interactions through multiple methods

• Dynamic cellular studies:

  • Create fluorescent protein fusions via CRISPR

  • Correlate live-cell imaging with fixed-cell antibody staining

  • Study protein dynamics in response to stimuli

  • Develop quantitative correlation metrics between methods

These CRISPR-based approaches provide orthogonal validation tools that complement antibody-based methods, enabling researchers to overcome limitations of either technology alone and build more robust evidence for At1g63370 function and interactions.